|
Innovative diagnostics may reduce ~9-year diagnosis delay, but systemic barriers to implementation remain.
|
 |
|
This acquisition will add Syfovre and Empaveli to Biogen’s portfolio of medicines.
|
|
|
Phase II CADENCE results position sotatercept as a potential first targeted therapy for CpcPH-HFpEF,.
|
|
|
At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, comparing single versus monthly dosing on blood pressure and a key biomarker.
|
|
|
Pending IND clearance, Telomir aims to start a Phase I/II clinical trial with Telomir-1 as oral treatment.
|
|
|
Symeres will assess Ambagon’s molecular glues through in vitro assays and mechanistic studies.
|
|
